Conjugate Vaccine Market Research Report - Global Forecast till 2023

1. Report Information More information from: https://www.marketresearchfuture.com/reports/4387 Conjugate Vaccine Market Research Report - Global Forecast till 2023 Report / Search Code: MRFR/HC/2981-HCRR Publish Date: January, 2019 Request Sample Price 1-user PDF : $ 4450.0 Enterprise PDF : $ 6250.0 Description: Global Conjugate Vaccines Market Research Report, By Type (Haemophilus B, Monovalent, Multivalent, And Others), By Indication (Influenza, Pneumococcal, Meningococcal, And Others) By End Users (Pediatrics And Adults) - Global Forecast Till 2023 Synopsis of the Global Conjugate vaccines Market Market Scenario Conjugate Vaccines are formed by covalently bonding a weak antigen to the strong antigen. This is done to boost the hosts’ immunological response. The poor antigen is a polysaccharide that is attached to the strong protein antigen. The major drivers for the growth of the global conjugate vaccine market are initiatives taken by the government, advancement in the vaccine formulation, and prevention of major infectious diseases, for instance meningitis and others. Furthermore, increasing investments by the companies in research & development, rising focus on immunization programs, and growing demand for vaccination expected to boost the growth of the market over the review period. Increasing prevalence of infectious diseases in children and rising number of awareness programs to promote vaccination will drive the growth of this market during the forecast period. The strength or effectiveness of conjugate vaccines needs to improve, which may hamper the growth of the market. The global conjugate vaccine market is expected to grow at a healthy CAGR of 10.5% during the forecast period 2017-2023. FIGURE 1 Global Conjugate Vaccines Market, by Indication, 2016 (%) Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation Intended Audience Research and development (R&D) companies

2. Government and independent research laboratories Government and independent regulatory authorities Academic medical institutes and universities Pharmaceutical industries Segments The global Conjugate vaccine is segmented on the basis of type, indication, and end users. On the basis type it is segmented into Haemophilus B, monovalent, multivalent, others. On the basis of indication, it is segmented into Influenza, Pneumococcal, Meningococcal, others. On the basis of end users, it is segmented into pediatrics and adults. Research Methodology Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation Regional Analysis of the Global Conjugate vaccines Market On the regional basis, the market is segmented into America, Europe, Asia Pacific and the Middle East & Africa. America dominates the largest market due to a significant use of the vaccine for preventing diseases and favorable conditions for research and development. Europe is the second largest Conjugate Vaccines market in the globe followed by Asia Pacific. In Europe availability of funds for research and development activities and growing emphasis on research for prevention measures of diseases is increasing. Whereas, Asia Pacific shows the fastest growth in this market due to the increasing prevalence of communicable diseases. Developing countries in this region are emphasizing research on diseases caused to children’s and preventive measures for treating them. Mainly, India and China are expected to be an emerging and the fastest growing market due to the increasing population and prevalence of diseases. The Middle East & Africa owns the lowest market in the global conjugate vaccines market due to less availability medical facilities. Key Players in the Global Conjugate vaccines Market Some of the key players in this market are GlaxoSmithKline plc. Merck & Co., Inc. (U.S), Fablife. (India), SutroVax

3. Inc.(U.S), Sanofi Pasteur SA.(France), Pfizer (U.S), Sinovac Biotech Ltd. (China), IDT Biologics GmbH, GreenSignal Bio Pharma Limited (India), Taj Pharmaceuticals Limited (India), Bavarian Nordic(U.S). Contents: Contents Table of Contents 1 Report Prologue 2 Market Introduction 2.1 Introduction 2.2 Scope of Study 2.3 Research Objective 2.4 Assumptions & Limitations 2.4.1 Assumptions 2.4.2 Limitations 3 Research Methodology 3.1 Research Process 3.2 Primary Research 3.3 Secondary Research 4 Market Dynamics 4.1 Drivers 4.2 Restraints 5 Market Factor Analysis 5.1 Porter’s Five Forces Model 5.1.1 Bargaining Power of Suppliers 5.1.2 Bargaining Power of Buyers 5.1.3 Threat of New Entrants 5.1.4 Threat of Substitutes 5.1.5 Intensity of Rivalry 5.2 Supply Chain Analysis 6. Global Conjugates Vaccines Market, by Type 6.1 Haemophilus B 6.2 Monovalent 6.3 Multivalent 6.4 Others 7. Global Conjugates Vaccines Market, by Indication 7.1 Influenza 7.2 Pneumococcal 7.3 Meningococcal 7.4 Others 8. Global Conjugates Vaccines Market, by End User 8.1 Pediatrics 8.2 Adults 9. Global Conjugates Vaccines Market, by Region 9.1 Introduction 9.2 America 9.2.1 North America 9.2.1.1 US 9.2.1.2 Canada 9.2.2 South America 9.3 Europe 9.3.1 Western Europe 9.3.1.1 Germany 9.3.1.2 UK 9.3.1.3 France 9.3.1.4 Italy 9.3.1.5 Spain 9.3.1.6 Rest of Western Europe 9.3.2 Eastern Europe 9.4 Asia Pacific 9.4.1 Japan 9.4.2 China 9.4.3 India 9.4.4 Australia 9.4.5 Republic of Korea 9.4.6 Rest of Asia Pacific 9.5 Middle East & Africa 9.5.1 United Arab Emirates 9.5.2 Saudi Arabia 9.5.3 Oman 9.5.4 Kuwait 9.5.5 Qatar 9.5.6 Rest of Middle East & Africa 10 Competitive Landscape 10.1 Cost of Products 10.2 Production Capacity of Major Players 11 Company Profile 11.1 GlaxoSmithKline plc. 11.1.1 Overview 11.1.2 Product/Business Segment Overview 11.1.3 Financial Updates 11.1.4 Key Developments

4. 11.2 Merck & Co., Inc. 11.2.1 Overview 11.2.2 Product/Business Segment Overview 11.2.3 Financial Updates 11.2.4 Key Developments 11.3 Fablife 11.3.1 Overview 11.3.2 Product/Business Segment Overview 11.3.3 Financial Updates 11.3.4 Key Development 11.4 Pfizer Inc 11.4.1 Overview 11.4.2 Product/Business Segment Overview 11.4.3 Financial Updates 11.4.4 Key Development 11.5 SutroVax Inc 11.5.1 Overview 11.5.2 Product/Business Segment Overview 11.5.3 Financial Updates 11.5.4 Key Developments 11.6 Taj Pharmaceuticals Limited 11.6.1 Overview 11.6.2 Product/Business Segment Overview 11.6.3 Financial Updates 11.6.4 Key Developments 11.7 Sanofi Pasteur SA 11.7.1 Overview 11.7.2 Product/Business Segment Overview 11.7.3 Financial Updates 11.7.4 Key Developments 11.8 Sinovac Biotech Ltd 11.8.1 Overview 11.8.2 Product/Business Segment Overview 11.8.3 Financial Updates 11.8.4 Key Developments 11.9 Bavarian Nordic 11.9.1 Overview 11.9.2 Product/Business Segment Overview 11.9.3 Financial Updates 11.9.4 Key Developments 11.9 Others 12 Conclusion 12.1 Key Findings 12.1.1 From CEO’s Viewpoint 12.1.2 Unmet Needs of the Market 12.2 Key Companies to Watch 12.3 Prediction of Conjugates Vaccines Industry 13 Appendix marketresearchfuture.com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349